SEC Form 4 · accession 0001127602-17-019588
Bioverativ Inc. · BIVV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander J Denner
Director
Period of report
May 24, 2017
Accepted (ET)
May 26, 2017 · 7:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681689
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F4,F5,F8,F11 | May 24, 2017 | P | 340,000 | $54.16 | A | 495,000 | I | See footnotes |
| Common StockF2,F4,F6,F9,F11 | May 25, 2017 | P | 130,000 | $54.9839 | A | 625,000 | I | See footnotes |
| Common StockF3,F4,F7,F10,F11 | May 26, 2017 | P | 450,000 | $57.2114 | A | 1,075,000 | I | See footnotes |
| Common Stock | holding | — | — | — | 5,001 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On May 24, 2017, each of Sarissa Capital Domestic Fund LP, a Delaware limited partnership ("Sarissa Domestic") and Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempt limited partnership ("Sarissa Offshore" and together with Sarissa Domestic, the "Sarissa Funds"), purchased an aggregate of 295,800 and 44,200 shares, respectively, of common stock of Bioverativ Inc.
- F10Includes (i) 895,471 shares beneficially owned by Sarissa Domestic and (ii) 179,529 shares beneficially owned by Sarissa Offshore.
- F11Alexander Denner, Ph.D. is the Chief Investment Officer of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F2On May 25, 2017, each of Sarissa Domestic and Sarissa Offshore purchased an aggregate of 113,100 and 16,900 shares, respectively, of common stock of Bioverativ Inc.
- F3On May 26, 2017, each of Sarissa Domestic and Sarissa Offshore purchased an aggregate of 391,500 and 58,500 shares, respectively, of common stock of Bioverativ Inc.
- F4Full information regarding the number of shares purchased at each separate price will be provided upon request by the SEC staff, the issuer or a security holder of the issuer.
- F5This represents the weighted average price for shares purchased at a range between $54.0278 (low) and $54.2631 (high).
- F6This represents the weighted average price for shares purchased at a range between $54.9826 (low) and $54.9994 (high).
- F7This represents the weighted average price for shares purchased at a range between $57.1471 (low) and $57.5297 (high).
- F8Includes (i) 390,871 shares beneficially owned by Sarissa Domestic and (ii) 104,129 shares beneficially owned by Sarissa Offshore.
- F9Includes (i) 503,971 shares beneficially owned by Sarissa Domestic and (ii) 121,029 shares beneficially owned by Sarissa Offshore.